Racura Oncology Appoints BDD for HARNESS-1 Trial
Filed with ASX · · 2 pages · English
§ The HARNESS-1 Phase 1a/b trial will recruit NSCLC patients with active EGFR mutation in five sites in Australia § Study will provide human safety, tolerability, pharmacokinetic, optimal dosage, and preliminary efficacy data with first patient expected to be recruited in Q1 CY2026. 24 December 2025 – Racura Oncology Limited (“Racura”) is pleased to announce that it has appointed the Contract Rese
Story so far
Earlier from Racura Oncology
- Race Oncology Completes $3.22m Private Placement
- Race Receives $2.8m RD Tax Refund
- HARNESS1 Lung Cancer Trial Receives Human Ethics Approval
- Race Clinical Program Update
- September 2025 Quarterly Activity Report and Appendix 4C
Later from Racura Oncology
- Racura Oncology Emory University Collaboration
- December 2025 Quarterly Activity Report and Appendix 4C
- Racura Develops Novel Cardioprotection Blood Test
- Appendix 4D & Half-Year Financial Statements
- Racura HARNESS-1 Trial Receives Governance Approval
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology